Vertex Pharmaceuticals Valuation Multiples

Vertex Pharmaceuticals Overview

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Founded

1989

HQ

Employees

6.4K

Website

vrtx.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $12B

EBITDA: $5B

EV

$119B

Valuation Multiples

Multiples.vc

Start free trial

Vertex Pharmaceuticals Financials

Vertex Pharmaceuticals reported last 12-month revenue of $12B and EBITDA of $5B.

In the same LTM period, Vertex Pharmaceuticals generated $11B in gross profit, $5B in EBITDA, and $5B in net income.

Vertex Pharmaceuticals P&L

In the most recent fiscal year, Vertex Pharmaceuticals reported revenue of $12B and EBITDA of $5B.

Vertex Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals has current market cap of $123B, and enterprise value of $119B.

Vertex Pharmaceuticals' stock price is $486.03.

Vertex Pharmaceuticals Valuation Multiples

Vertex Pharmaceuticals trades at 9.7x EV/Revenue multiple, and 21.9x EV/EBITDA.

Vertex Pharmaceuticals Financial Valuation Multiples

As of April 8, 2026, Vertex Pharmaceuticals has market cap of $123B and EV of $119B.

Equity research analysts estimate Vertex Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Vertex Pharmaceuticals has a P/E ratio of 25.8x.

Vertex Pharmaceuticals Margins & Growth Rates

Vertex Pharmaceuticals' revenue in the last 12 month grew by 9%.

Vertex Pharmaceuticals' revenue per employee in the last FY averaged $1.9M, while opex per employee averaged $0.9M for the same period.

Vertex Pharmaceuticals' rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Vertex Pharmaceuticals' rule of X is 66% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Vertex Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Vertex Pharmaceuticals M&A Activity

Vertex Pharmaceuticals acquired XXX companies to date.

Last acquisition by Vertex Pharmaceuticals was on XXXXXXXX, XXXXX. Vertex Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Vertex Pharmaceuticals Investment Activity

Vertex Pharmaceuticals invested in XXX companies to date.

Vertex Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Vertex Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).